Lipoprotein particles and incident type 2 diabetes in the multi- ethnic study of atherosclerosis

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 628-636

  MacKey, Rachel H ^a   Mora, Samia ^b   Bertoni, Alain G ^c   Wassel, Christina L ^a   Carnethon, Mercedes R ^d   Sibley, Christopher T ^e   Goff, David C ^f  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHYSICAL ACTIVITY; RACE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; ETHNIC GROUP; ETHNOLOGY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; INSULIN RESISTANCE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTICLE SIZE; TRIGLYCERIDES;

EID: 84962135661     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0645     Document Type: Article

References (33)

1. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686.
2. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012;32:2104-2112.
3. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462.
4. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54: 264-270.
5. Wang J, Staňćakova A, Soininen P, et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: A population-based study of 9399 Finnish men. J Intern Med 2012;272:562-572.
6. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005;111: 3465-3472.
7. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010;59:1153-1160.
8. Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract 2009;83:132-139.
9. Otvos JD, inventor; LipoScience, Inc, assignee. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same. U.S. patent 8, 386, 187. 26 February 2013.
10. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: A lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord 2014; 12:422-429.
11. Mikus CR, Patel MJ, Slentz CA, Bateman LA, Willis LH, Kraus WE. Comparison of lipoproteinderived insulin resistance score and standard measures of insulin sensitivity. Diabetes 2013; 62(Suppl. 1):A167.
12. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010;30:1642-1648.
13. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012;8: 237-245.
14. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22:26-32.
15. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
16. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011;305:2556-2564.
17. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172: 144-152.
18. Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobinA1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555-562.
19. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-478.
20. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57: 1535-1545.
21. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am J Cardiol 2002;90(8A): 71i-76i.
22. Hsia J, Otvos JD, Rossouw JE, et al.; Women's Health Initiative Research Group. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative hormone trials. Arterioscler Thromb Vasc Biol 2008;28:1666- 1671.
23. Bertoni AG, Burke GL, Owusu JA, et al. Inflammation and the incidence of type 2 diabetes: theMulti-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010;33:804-810.
24. Lutsey PL, Pereira MA, Bertoni AG, Kandula NR, Jacobs DR Jr. Interactions between race/ethnicity and anthropometry in risk of incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2010;172:197-204.
25. Bild DE, Bluemke DA, Burke GL, et al. Multi- Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-881.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
27. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26:847-870.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-152.
30. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: A randomized, double-blind, controlled study. Diabetes Care 2009;32:1087- 1091.
31. Rashedi N, Brennan D, Kastelein JJ, Nissen SE, Nicholls S. Impact of cholesteryl ester transfer protein inhibition on nuclear magnetic resonance derived lipoprotein particle parameters. Atheroscler Suppl 2011;12:48.
32. Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 2012;163: 515-21, 521e1-3.
33. Jafri H, Alsheikh-Ali AA, Mooney P, Kimmelstiel CD, Karas RH, Kuvin JT. Extendedrelease niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol 2009;3: 45-50.